Severe deficiency of VWF‐cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients

Abstract

In a heterogeneous population of TMA patients treated with plasma exchange, ADAMTS13 activity defined two subpopulations with distinct clinical and laboratory features. These results suggest that TMA with severe ADAMTS13 deficiency is a distinct pathologic process.